Repare Therapeutics Inc. (NASDAQ:RPTX) is Blue Owl Capital Holdings LP’s 10th Largest Position

Blue Owl Capital Holdings LP raised its position in Repare Therapeutics Inc. (NASDAQ:RPTX) by 8.0% in the second quarter, Holdings Channel reports. The institutional investor owned 3,372,499 shares of the company’s stock after purchasing an additional 250,000 shares during the period. Repare Therapeutics accounts for about 3.1% of Blue Owl Capital Holdings LP’s portfolio, making the stock its 10th largest position. Blue Owl Capital Holdings LP owned about 0.08% of Repare Therapeutics worth $11,129,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new stake in shares of Repare Therapeutics during the second quarter worth about $110,000. Opaleye Management Inc. purchased a new stake in shares of Repare Therapeutics during the first quarter worth about $318,000. Marshall Wace LLP purchased a new stake in shares of Repare Therapeutics during the second quarter worth about $273,000. Bank of Montreal Can increased its stake in shares of Repare Therapeutics by 5.4% during the second quarter. Bank of Montreal Can now owns 110,935 shares of the company’s stock worth $366,000 after purchasing an additional 5,673 shares in the last quarter. Finally, Acadian Asset Management LLC increased its stake in shares of Repare Therapeutics by 53.5% during the first quarter. Acadian Asset Management LLC now owns 133,893 shares of the company’s stock worth $625,000 after purchasing an additional 46,648 shares in the last quarter. Hedge funds and other institutional investors own 85.09% of the company’s stock.

Repare Therapeutics Stock Performance

RPTX opened at $3.44 on Friday. Repare Therapeutics Inc. has a twelve month low of $2.71 and a twelve month high of $12.72. The firm’s 50-day moving average price is $3.22 and its 200 day moving average price is $3.58.

Repare Therapeutics (NASDAQ:RPTX) last posted its earnings results on Tuesday, August 6th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.03. The company had revenue of $1.07 million for the quarter, compared to analyst estimates of $4.02 million. Repare Therapeutics had a negative net margin of 99.76% and a negative return on equity of 31.11%. As a group, sell-side analysts predict that Repare Therapeutics Inc. will post -2.15 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Repare Therapeutics in a research note on Monday, September 23rd. Lifesci Capital upgraded shares of Repare Therapeutics to a “strong-buy” rating in a research report on Monday, July 29th.

Repare Therapeutics Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.